Investors sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman
January 25, 2024 12:34 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 –...
BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman
January 22, 2024 20:29 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 –...